We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Boehringer Ingelheim’s Spiriva Respimat for COPD
FDA Approves Boehringer Ingelheim’s Spiriva Respimat for COPD
Boehringer Ingelheim won FDA approval Thursday for its chronic obstructive pulmonary disease (COPD) drug Spiriva Respimat and plans to launch the drug by the new year.